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ABSTRACT The intracellular parasite Toxoplasma gondii infects a wide variety of vertebrate species globally. Infection in most
hosts causes a lifelong chronic infection and generates immunological memory responses that protect the host against new infec-
tions. In regions where the organism is endemic, multiple exposures to T. gondii likely occur with great frequency, yet little is
known about the interaction between a chronically infected host and the parasite strains from these areas. A widely used model
to explore secondary infection entails challenge of chronically infected or vaccinated mice with the highly virulent type I RH
strain. Here, we show that although vaccinated or chronically infected C57BL/6 mice are protected against the type I RH strain,
they are not protected against challenge with most strains prevalent in South America or another type I strain, GT1. Genetic and
genomic analyses implicated the parasite-secreted rhoptry effectors ROP5 and ROP18, which antagonize the host’s gamma
interferon-induced immunity-regulated GTPases (IRGs), as primary requirements for virulence during secondary infection.
ROP5 and ROP18 promoted parasite superinfection in the brains of challenged survivors. We hypothesize that superinfection
may be an important mechanism to generate T. gondii strain diversity, simply because two parasite strains would be present in a
single meal consumed by the feline definitive host. Superinfection may drive the genetic diversity of Toxoplasma strains in South
America, where most isolates are IRG resistant, compared to North America, where most strains are IRG susceptible and are de-
rived from a few clonal lineages. In summary, ROP5 and ROP18 promote Toxoplasma virulence during reinfection.
IMPORTANCE Toxoplasma gondii is a widespread parasite of warm-blooded animals and currently infects one-third of the hu-
man population. A long-standing assumption in the field is that prior exposure to this parasite protects the host from subse-
quent reexposure, due to the generation of protective immunological memory. However, this assumption is based on clinical
data and mouse models that analyze infections with strains common to Europe and North America. In contrast, we found that
the majority of strains sampled from around the world, in particular those from South America, were able to kill or reinfect the
brains of hosts previously exposed to T. gondii. The T. gondii virulence factors ROP5 and ROP18, which inhibit key host effec-
tors that mediate parasite killing, were required for these phenotypes. We speculate that these results underpin clinical observa-
tions that pregnant women previously exposed to Toxoplasma can develop congenital infection upon reexposure to South Amer-
ican strains.
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Toxoplasma gondii is an intracellular zoonotic pathogen thatchronically infects awide range of vertebrate species, including
sea and land mammals, a variety of birds, and an estimated one-
third of the human population. In intermediate hosts, there are
two developmental life stages: the fast-dividing tachyzoite stage,
which is responsible for acute disease, dissemination, and pathol-
ogy, and the slow-growing bradyzoite stage, which is responsible
for chronic infection and tissue cyst formation. Once infected,
most intermediate hosts are chronic carriers for life and develop
immunological memory responses that protect the host against
reinfection (1) and keep the parasite in its semidormant, chronic
stage (2). Members of the cat family are the definitive host and
shed infectious oocysts into the environment. Transmission be-
tween hosts occurs following ingestion of either tissue cysts or
oocysts. Toxoplasma oocysts are initially diploid and undergo one
round of meiosis during sporulation in the environment, a char-
acteristic of coccidian parasites (3). Because Toxoplasma can self-
mate, the resultant sporozoites are clonal if a cat ingests one par-
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asite strain, but recombinant progeny can be produced when a cat
is infected with two or more different strains.
Despite the potential for genetic recombination, this appears
to be a rare event on certain continents (4). For example, in North
America and Europe, the population structure of T. gondii is re-
markably clonal, with four lineages (the clonal or canonical types
I, II, and III and type 12) accounting for the majority of isolated
strains (4–6). In contrast, T. gondii strains from other parts of the
world (often called atypical or exotic strains), and in particular
those from South America, lack a clonal population structure and
exhibit genetic diversity. Atypical strains can be clustered into
haplogroups (HGs) 4 to 15, but most HGs are not clonal (7–11),
and there is evidence for increased sexual recombination in South
American strains (10, 12). It is unclear why the population struc-
ture is linked to geography, but several hypotheses have been put
forward, including selective sweeps driven by advantageous whole
chromosomes (4), the disappearance of cats in North America
during the Great Ice Age extinction event (8), clonal outbreaks
due to self-mating in the cat (13), and diversification within the
species-rich jungles of South America (14). Given that Toxo-
plasma is a globally ubiquitous parasite and infection rates can be
high in certain locales, T. gondii likely encounters hosts with prior
immunity toT. gondii. However, little is known regarding parasite
survival within an immune host and whether there are specialized
virulence factors that promote reinfection. Because secondary in-
fection may significantly impact the Toxoplasma population
structure, we decided to explore the pathogenesis of a panel of T.
gondii strains isolated from around the world by infecting chron-
ically infected hosts.
Studies on the pathogenesis of Toxoplasma have mainly fo-
cused on primary infectionmousemodels andToxoplasma strains
isolated fromNorthAmerica and Europe. Type I strains are highly
virulent (100% lethal dose [LD100], 1 parasite) but rarely isolated,
while types II, III, and 12 are less virulent (LD50s of ~103, ~105,
and ~103 parasites, respectively) and frequently observed (5). Us-
ing these strains, key virulence factors that inhibit downstream
toxoplasmacidal mechanisms elicited by the proinflammatory cy-
tokine gamma interferon (IFN-) have been found to explain the
relative differences in virulence during primary infection. IFN-
induces the expression of two classes of GTPases, the immunity-
regulated GTPases (IRGs) and guanylate-binding proteins
(GBPs), which are important host resistance factors to pathogens
that reside in vacuoles, likeToxoplasma,Chlamydia, andMycobac-
terium species (15). When Toxoplasma infects a cell previously
stimulated with IFN-, the absence of regulatory GMS IRGs (16)
on the parasitophorous vacuole membrane (PVM) leads to PVM
localization of the GKS class of effector IRGs (17) andmany GBPs
(18), causing PVM destruction and rapid parasite death (19–22).
The Toxoplasma rhoptry (ROP) kinases ROP18 and ROP17, the
dense granule GRA7, and the ROP5 pseudokinases are secreted
into the host cell upon invasion and subsequently traffic back to
the PVM, where they cooperatively inhibit the localization and
function of IRGs (23–30) and GBPs (21, 31). Differences in viru-
lence between the clonal lineage strains are the result of polymor-
phisms in the ROP5 (32, 33) and ROP18 effectors (34, 35), with
smaller contributions from other genetic loci (36). The type I
strains encode virulent alleles of the ROP5 and ROP18 effectors,
while the type II and III strains encode combinations of less viru-
lent alleles that render them more susceptible to IRG-mediated
killing and therefore less virulent in mice. The few atypical strains
that have been studied are extremely virulent in naive mice (37),
and most encode combinations of the ROP5/ROP18 alleles that
are predicted to confer IRG resistance (26). Whether atypical
strains have novel virulence factors is unknown.
The majority of studies on secondary infection have also fo-
cused on clonal lineage strains. Whereas naive mice are extremely
susceptible to the type I RH strain or high-dose infections with
type II strains, chronically infected or vaccinated mice are not
(38). Inmousemodels of chronic infection, T cells and IFN- play
pivotal roles in preventing reactivation of the dormant form (2,
39). These results mirror clinical observations of HIV/AIDS pa-
tients, in whom deterioration of memory T cells correlates with
toxoplasmic encephalitis. In mouse vaccination studies, CD8 T
cells are themainmediators of protection against lethal secondary
challenges (40–43). Protective CD8 T cells require CD4 T cell help
(42, 44, 45) and interleukin-12 (IL-12) during priming (46, 47),
and protection is dependent on IFN- (41) and possibly tumor
necrosis factor alpha (TNF-) and lymphotoxin-alpha (48), but
not perforin (49). The importance of cytolysis and inducible nitric
oxide synthetase appears to be limited to chronic infection
(50–52).
Several studies have aimed to understand how well infection
with one strain protects against reinfection with another, i.e.,
“heterologous immunity.” In regions of endemicity, for example,
in Brazil and France, approximately 50 to 80% of the human pop-
ulation has been exposed to the parasite, and multiple exposures
are likely the norm. However, because of the genetic diversity in
South America and dominance of type II strains in Europe, sec-
ondary infections in South America will more often occur with a
different strain type. In mouse models of reinfection, a study of
124 isolates from North and Central America, Europe, and the
Pacific Islands demonstrated significant heterologous immunity
(53). Likewise, vesper mice chronically infected with a type II
strainwere protected from congenital infectionwith a type I strain
(54). Large parts of the type I and III genome are derived from the
type II strain, and there is evidence for genomic introgression of
the type II strain into South American strains (8, 55). Heterolo-
gous immunity may thus be achieved because immunodominant
antigens are encoded by shared genomic regions or because Tox-
oplasma strains are generally ~99% similar. In contrast, type
I-vaccinated rats were not protected against congenital T. gondii
infection following oral ingestion of tissue cysts from several
strains (56), and inmice chronic infection with certain strains did
not generate heterologous immunity to congenital infection (57)
or lethal oral challenge with a different strain (58). A few studies
have addressedwhat happens to the challenging strain during het-
erologous challenge, and those investigators noted that with cer-
tain strains and host genetic backgrounds, successful coinfection
in the brain can occur (59–61). Thus, the outcome of secondary
exposure could be the result of several factors, including the ability
of memory cells to recognize the second strain, the type of inter-
mediate host, and unique virulence attributes of the strain causing
the secondary infection.
Very little is known about requirements for host immunity to
atypical strains. This is important because there is evidence that
the severity of human toxoplasmosis is influenced by the parasite
genotype and geographic location. Congenitally infected Brazilian
children or South American patients with ocular toxoplasmosis
present a more severe form of eye disease than those in other
locales (62–64), and PCR-based strain typing methods suggest
Jensen et al.
















atypical strain infections in Brazil or type I/atypical infections in
Europe andNorthAmerica are associatedwithmore severe ocular
toxoplasmosis (65–68). Additionally, severe congenital infection
in North America is associated with non-type II strains (69). Im-
portantly for this current study, there have been cases where sero-
positive healthy women developed acute toxoplasmosis and con-
genital infection during pregnancy; in one instance when the
responsible strain was genotyped it was an atypical strain (70, 71).
Whether type I or atypical strains possess unique virulence factors
that make them highly virulent in human populations is un-
known.
Since most studies on T. gondii strain differences in virulence
have focused on primary infection models using the European-
North American strains, we asked whether Toxoplasma strains
differ in virulence during secondary infection and sampled a
broad spectrum of T gondii strains isolated from around the
world. Here we present evidence that the majority of Toxoplasma
strains are able to kill chronically infected or vaccinated C57BL/6
(B6) mice, including mice vaccinated and subsequently chal-
lenged with the same strain type. Toxoplasma expression of the
virulent alleles ofROP5 andROP18 is a requirement for secondary
infection virulence and superinfection of chronically infected
mice. We hypothesize that superinfection through IRG resistance
promotes outcrossing, because two strains would be present in a
single rodent meal for the cat. This would make it difficult to
maintain a clonal population structure.
RESULTS
The atypical strain MAS is virulent during secondary infection.
We first explored whether chronic infection conferred protective
immunity to secondary infection by working with a nonclonal
lineage strain, the atypical strain MAS (haplogroup 4). The MAS
strain was originally isolated from a patient with disseminated
congenital infection (72) and is highly virulent in naive mice (37).
C57BL/6 mice were infected with an avirulent type III strain
(CEP) and allowed to progress to chronic infection for 35 to
60 days before secondary infection. While the majority of mice
survived a secondary infection (i.e., challenge) with the type I RH
strain, as expected, approximately 50% of chronically infected
mice succumbed to secondary infection with the atypical strain
MAS (Fig. 1A).Moreover, surviving and nonsurvivingmice expe-
rienced significant weight loss and morbidity during secondary
challenge with the MAS strain (Fig. 1B). In contrast, mice chal-
lenged with the type I RH strain experienced little weight loss or
morbidity following secondary infection.
Since the clonal strain types (I, II, and III) and atypical strains
may express different antigens, we wondered whether strain-
specific immunity was generated by the previous immunization
regimen. Therefore, C57BL/6 mice were vaccinated with theMAS
strain. This was achieved by treating mice with the antiparasitic
drugs pyrimethamine and sulfadiazine 1 day after initial infection
and giving subsequent “priming” injections with live MAS para-
sites during drug administration. Two weeks after drug removal,
MAS-vaccinatedmice survived challengewith the type I RH strain
but not the atypical strain MAS (Fig. 1C). MAS-challenged mice
were less able to control parasite replication than were type I RH-
challenged mice, as evidenced by bioluminescence imaging
(luciferase-expressing MAS-Luc and RH-Luc strains) (Fig. 1D
and E) and experienced significant weight loss (Fig. 1F). Thus, two
different priming conditions that generated protective immuno-
logical memory to the type I RH strain failed to do so for the
atypical strain MAS.
The CD8 T cell IFN- response to the atypical strain MAS is
unimpaired. Given the central role of CD8 T cells and IFN- in
mediating host immunity to secondary Toxoplasma infection
(38), we tested whether the CD8T cell IFN- response to theMAS
strain was impaired. To this end, peritoneal exudate cells (PECs)
and splenocytes from type III chronically infected mice were in-
fected in vitro with either the atypical strain MAS or the type I
strain (“recall infection”), and the CD8 T cell IFN- response was
measured 16 h later by intracellular cytokine staining and
fluorescence-activated cell sorting (FACS) analysis. No differ-
ences in the frequencies of IFN- CD8 T cells were observed
following recall infections with the various Toxoplasma strains
(Fig. 2A). Total amounts of IFN-, IL-2, and TNF- were mea-
sured in the supernatants following recall infections, and no dif-
ferences in cytokine production were observed betweenMAS and
clonal strain type infections (data not shown).We noted that type
III chronic infection elicited a robust peritoneal but not splenic
CD8 T cell IFN- recall response (Fig. 2A andC). In contrast, type
II chronic infection elicited a detectable CD8 T cell IFN- recall
response from both compartments (Fig. 2B and C). Nonetheless,
similar frequencies of IFN- CD8 T cells were also observed
from the spleens and PEC compartments of type II chronically
infected mice following recall infections with different parasite
strains (Fig. 2C). CD8-negative CD3 T cells, the majority of
which are CD4 T cells, were also analyzed in these experiments,
and similar results were obtained (data not shown).
IFN--producing CD8 T cells from chronically infected mice
were further analyzed forCD62L andKLRG1 expression, which in
combination can approximate effector memory T cells (TEM;
CD62LCD44 IL7rKLRG1/) and central memory CD8 T
cell (TCM; CD62LCD44 IL7rKLRG1) populations. CD8T
cells expressing these markers have different turnover rates (73),
homing characteristics (74), priming requirements (46), and T
cell receptor (TCR) repertoires (75), and hence they may vary in
their responses to the MAS and type I strains, leading to differ-
ences in host susceptibility. Although the relative frequency of
CD62L and/or KLRG1 IFN- CD8 T cell PECs varied be-
tween individual type III chronically infected mice, at an individ-
ual mouse level the frequencies of these populations were equiva-
lent following recall infections with the MAS and clonal parasite
strains (see Fig. S1A in the supplemental material). Additionally,
IFN- CD8 T cells from the spleens of type II chronically in-
fected mice had similar IL-7r hi expression following recall in-
fections with type I and MAS strains (see Fig. S1B). These results
suggest that memory CD8 T cells expressingmarkers that approx-
imate the TEM and TCM memory pools are not initially biased in
their IFN- response to different T. gondii strains.
In the experiments described above, we analyzed polyclonal
memory CD8 T cells with unknown antigen specificities. In the
C57BL/6 background (H-2b haplotype), a peptide epitope recog-
nized by CD8 T cells has been identified and is derived from a
Toxoplasma protein, TGD057 (TgME49_215980), with unknown
function (76). Mice have been cloned from the nucleus of a single
Toxoplasma-specific CD8 T cell (“transnuclear mice”) bearing T
cell receptor specificity for the TGD05796–103 peptide in complex
with the Kbmajor histocompatibility complex (MHC) class Imol-
ecule, and adoptive transfer of CD8 T cells (T57 cells) from these
transnuclear mice confers increased host resistance to infection
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with type II strains (77). Therefore, the naive T57 CD8 T cell
cytokine responses to bone marrow-derived macrophages
(BMDMs) infected with different parasite strains were measured
in an enzyme-linked immunosorbent assay (ELISA), including
the response to BMDMs infected with a type I strain in which the
TGD057 gene was removed by double homologous recombina-
tion (I tgd057) (see Fig. S2 in the supplemental material). The
T57 IFN- and IL-2 responses were 5 to 10 times greater to
BMDMs infectedwith theMAS strain than those infectedwith the
type I strain, and as expected, no response was observed to
BMDMs infected with type Itgd057 parasites (Fig. 2D). Of note,
the TGD05796–103 peptide epitope is conserved between parasite
strains. In conclusion, the atypical strain MAS elicits a robust na-
ive and memory CD8 T cell IFN- response, suggesting that im-
munological failure during secondary challenge does not correlate
with impairedCD8T cell recognition or the IFN- response to the
atypical strain MAS.
Toxoplasma ROP5 and ROP18 are major virulence determi-
nants during secondary infection with atypical strains.To inves-
tigate whether compromised host immunity occurred with other
atypical strains, we chronically infected C57BL/6 mice with the
avirulent type III strain as described before and then challenged
these mice 35 to 65 days later with a panel of atypical strains that
are highly virulent in naive mice (Fig. 3A) and can be loosely
grouped according to their genotype as follows (haplogroups are
in parentheses): CASTELLS (HG 4); GUY-KOE (HG 5); FOU,
BOF, and GPHT (HG 6); CAST (HG 7); TgCATBr5 (HG 8); P89
(HG 9); GUY-DOS and VAND (HG 10); COUGAR (HG 11). We
noted that atypical strains that resisted IRG-mediated killing in
IFN--stimulated mouse embryonic fibroblasts (MEFs; “IRG re-
sistant”) caused between 50% and 100%mortality during second-
ary infection (Fig. 3B). In contrast, P89, CASTELLS, COUGAR,
and BOF, which do not prevent IRG-mediated killing mecha-
nisms in MEFs (“IRG susceptible”) (26), caused 0% mortality
FIG 1 Compromised host immunity to the atypical T. gondii strain MAS. (A) C57BL/6 mice were infected (i.p.) with an avirulent type III strain (CEP) and
allowed to progress to chronic infection. Thirty-five to 70 days later, mice were challenged (i.p.) with 5 104 tachyzoites of either the atypical MAS or type I RH
strains. Results were compiled from 6 to 8 independent experiments, and the percent survival following challenge is plotted for each strain. The number of mice
in each group (n) is indicated; **, P value was calculated by a log-rank Mantel-Cox test and was considered significant. (B) The average relative weights SEM
ofmice that did not survive secondary infection with theMAS strain and of those that survived RH andMAS secondary infections are shown; for eachmeasured
time point, the fraction of initial weight at the time of challenge (day zero weight 1) were plotted. Results are cumulative from 5 independent experiments, and
the number of mice (n) in each group is indicated. **, P  0.009; significant by analysis of variance testing; §, P  0.04 based on two-tailed Student’s t test,
comparing the relative weights between survivors of type I RH andMAS secondary challenges. (C) Cumulative survival, combined from 2 experiments, in which
C57BL/6 mice were vaccinated with the atypical strain MAS and challenged with either the MAS-Luc or type I RH-Luc strain; the number (n) of mice in each
group is indicated and all mice were seropositive prior to challenge (see Materials and Methods). In the absence of vaccination, MAS-infected and type I
RH-infected mice died between days 5 and 8 postinjection (data not shown). (D) Representative bioluminescence imaging of 2 individual mice challenged with
the MAS-Luc strain and 1 mouse challenged with the RH-Luc strain (from the experiments described for panel C). The relative parasite burden is depicted as a
heat map: maximum 105, minimum 3 103 (photons/s/cm2/sr). MAS-challengedmouse 1 was euthanized on day 27 because it had a poor body condition
score (BC, 2) andwas continuing to lose weight;MAS-challengedmouse 2 died on day 5. (E) Average luciferase activity (in photons/s/cm/sr2, SEM) for each
cohort following challenge with the type I RH-Luc (n  3) or MAS-Luc (n  4) strains. Data shown are from a single experiment representative of two
experiments. *,P 0.05 (Student’s t test). (F) Results obtained from the same experiment described in panel C, but the average fraction of initial weight ( SEM)
of mice following secondary infection with the MAS and RH strains is shown. *, P 0.05 (Student’s t test).
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(P89, BOF, andCASTELLS) or 22%mortality (COUGAR) during
secondary infection (Fig. 3C). In the case of P89 and CASTELLS,
these strains do not express ROP18, whereas BOF has the virulent
ROP18 allele but has very low expression ofROP5 (26). COUGAR
expresses the virulent allele of ROP18 and some members of the
ROP5 locus, but possibly because it lacks the ROP5C allele this
strain remains sensitive to IFN--mediated killing (26). Thus,
there is a positive correlation between atypical Toxoplasma strains
that inhibit IRG function throughROP5 andROP18 and killing of
chronically infected mice.
To test whether restoration of IRG resistance in an atypical
strain can promote virulence during a secondary infection, mice
were chronically infected with the type III strain as before and
challenged with an atypical BOF strain engineered to express the
entire ROP5 locus of the type I strain (BOF ROP5I). Compared
to the parental strain, BOF ROP5I survives significantly better in
IFN--stimulated MEFs and inhibits IRGB6-PVM coating (26).
Unlike the BOF strain, challenge with the BOF ROP5I strain
caused host death (40% of the cohort) and morbidity, as evi-
denced by weight loss (	5% weight loss) during secondary infec-
tion (Fig. 3D and E). These results underpin the notion that IRG
resistance during a heterologous challenge is an important attri-
bute for parasite virulence.
TheToxoplasmaROP5/SAG3 locus correlates with virulence
during secondary infections with F1 progeny derived from
clonal lineage strains. The type I RH strain is highly virulent in
naive mice due to expression of the virulent ROP5 and ROP18
alleles (28, 33, 78, 79), but RH was the only IRG-resistant strain
that failed to induce morbidity in chronically infected mice
(Fig. 1A). This strain has a long laboratory passaging history (80)
of at least 50 years prior to the experiments performed in this
study, and over time it has accumulated hundreds of mutations
and gene expression differences compared to other type I strains
(80, 81). Thus, chronically infected mice were challenged with
another type I strain called GT1, which was originally isolated
from a deceased goat in North America (82). Importantly, the
GT1 strain killed type III chronically infected mice (Fig. 4A). To
test whether GT1 could also kill mice vaccinated with a type I
strain, mice were immunized with the replication-deficient uracil
auxotroph type I RH ompdc up vaccine strain (83) and chal-
FIG 2 The CD8 T cell IFN- response to the atypical strain MAS is unimpaired. (A) PECs and splenocytes were obtained from an individual C57BL/6 mouse
chronically infected with the type III (CEP) strain and were then infected in vitro (i.e., “recall” infections) with the indicated parasite strain (MOI, 0.2). Sixteen
hours later, CD8 T cells were analyzed for intracellular IFN- by FACS analysis. The percentage of CD8 (CD3 CD19) T cells that were positive for IFN-
within the indicated gate following recall infection is shown. (B) Results of an experiment similar to that of panel A, except recall infections were performed using
PECs and splenocytes from a type II (Pru) chronically infected mouse. (C) Cumulative data showing the average frequency ( SEM) of IFN- CD8 (CD3
CD19) T cells fromPECs (3 experiments; n 7mice) and spleens (1 experiment; n 3mice) from type III (CEP) chronically infected C57BL/6mice and PECs
(2 experiments; n 5 mice) and spleens (2 experiments; n 6 mice) from type II (Pru) chronically infected C57BL/6 mice. Average frequencies obtained from
recall infections with the type I RH strain and MAS strain are plotted. Significant differences in the average frequencies between RH and MAS recall infections
were calculated with Student’s t test; *n.s., not significant (P	 0.05). (D) Naive TGD05796–103-specific T57 transnuclear CD8 T cells (77) were cocultured with
BMDMs infected with the indicated parasite strain (MOI, 0.2) in triplicate. The average amounts ( standard deviation) of IFN- and IL-2 detected in the
supernatants via an ELISA 48 h later are plotted. *, P 0.05 (Student’s t test). Results are representative of 5 independent experiments.
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lenged with either the RH or GT1 type I strain. Again, GT1 chal-
lenge, but not RH challenge, led to death of vaccinated mice
(Fig. 4B) and mice rapidly lost weight prior to death (data not
shown).
To determine genetic loci underlying the ability of Toxoplasma
to kill an immune host, type III chronically infectedC57BL/6mice
were challenged with F1 recombinant progeny derived from a
cross between the virulent type I GT1 and the avirulent type III
CTG strains (I III F1 progeny). In previous studies using these
progeny, the ROP18 gene was the primary gene responsible for
parasite virulence in naive mice (34) and, therefore, we excluded
progenywhich harbored the avirulent type IIIROP18 allele, which
is not expressed due to an insertion in its promoter (34, 35). In this
screen of 16 F1 I  III progeny (which all are virulent for naive
mice), mouse survival significantly correlated with the SAG3
marker (LOD, 4.1; P  0.05) on Toxoplasma chromosome XII
(Fig. 4C), which is the genetic marker closest to the ROP5 locus.
Effect plots revealed that type I alleles at the SAG3 locus signifi-
cantly correlated with mouse mortality during secondary infec-
tion (type I allele, 0% 0% survival [mean standard deviation];
type III allele, 80% 35% survival; P 0.0001) (Fig. 4D; see also
Fig. S3 in the supplemental material).
Toxoplasma ROP5 and ROP18 promote superinfection in
chronically infected mice. To extend the analysis of the role of
Toxoplasma resistance to IRG-mediated killing in virulence dur-
ing a secondary infection, a panel of ROP5- and/or ROP18-
expressing parasite strains was screened for virulence in type III
chronically infected mice. First, the IRG-sensitive type II and type
III strains engineered to become IRG resistant through ROP5
(IIROP5I) and ROP18 (IIIROP18I) expression, respectively,
induced morbidity during secondary infection but failed to kill
chronically infected mice (Fig. 5A and B), even though these
strains are virulent in naive mice (26, 84). Second, the highly vir-
ulent S23 strain, an F1 progeny derived from a cross between a
type II and a type III strain (II  III) that expresses virulent
ROP5III and virulentROP18II alleles (85), inducedmorbidity dur-
ing secondary infection but did not kill chronically infected mice
(Fig. 5A and B). Finally, the avirulent and IRG-sensitive S22 F1
(II III) strain engineered to express ROP5I and ROP18II (S22
ROP5I  ROP18II), making this strain IRG resistant and highly
virulent in naive mice (26), induced morbidity but not host death
during secondary challenge.
Although mice survived challenge with the aforementioned
IRG-resistant parasite strains, they each experienced various de-
FIG 3 T. gondiiROP5- andROP18-expressing atypical strains cause lethal secondary infection. (A)Naive C57BL/6mice were infected (i.p.) with 103 tachyzoites
of the type I RH strain or 1 of 12 atypical strains:MAS andCASTELLS (HG4); GUY-KOE (HG5); FOU, BOF, andGPHT (HG6); CAST (HG7); TgCATBr5 (HG
8); P89 (HG9);GUY-DOS andVAND(HG10); COUGAR (HG11). The average survival times ofmice infectedwith the type I RH strain, the atypical BOF strain,
or the remaining 11 atypical strains are shown. Two to four individual mice per parasite strain were infected, with the exception of BOF, for which 9 mice were
infected. (B) C57BL/6mice were infected (i.p.) with the avirulent type III (CEP) strain and allowed to progress to chronic infection; 35 to 65 days later, mice were
challenged (i.p.) with 5  104 tachyzoites of the indicated atypical strains previously shown to inhibit IRGB6 parasitophorous vacuole (PV) coating (IRG
resistant) (26). Three to eight individual mice per parasite strain were challenged, and the cumulative survival is plotted. (C) Results of an experiment similar to
that in panel B, but atypical strains that are highly susceptible to parasite killing and IRGB6-PV coating in IFN--stimulatedMEFs (IRG-susceptible) were used.
Four individual mice were challenged with the BOF or P89 strain and 9mice were challenged with COUGAR. Cumulative survival is plotted. (D) C57BL/6 mice
were infected with the type III strain (CEP) and allowed to progress to chronic infection. Seventy days later, mice were challenged (i.p.) with 5 104 tachyzoites
of either the atypical BOF strain, which expresses ROP18 and very low levels of ROP5 (26), or the BOF strain engineered to express the entire type I ROP5 locus
via cosmid integration (BOF ROP5I). Cumulative survival of 5 mice per parasite strain is plotted. (E) Results were obtained from the same experiment shown
in panel D, but the average relative weights ( SEM) of mice following secondary infection with the BOF or BOF  ROP5I strain are shown. *, P  0.05; **,
P 0.008 (Student’s t test).
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grees of sickness, as evidenced by weight loss after challenge. In
contrast, challenge with the parental control or IRG-susceptible
strains led to no appreciable morbidity or weight loss (Fig. 5B).
Importantly, IRG-resistant BOF  ROP5I, S22  ROP5I 
ROP18II, II  ROP5I, and III  ROP18I strains and the virulent
S23 strain could be detected in parasite cultures generated from
the brains of the challenged survivors (termed “superinfec-
tion” here), whereas the parental strains could not be rederived
(Table 1). Heterologous brain infections were observed in
other challenge experiments, including chronically infected
animals challenged with GUY-KOE, but not after challenge
with the IRG-susceptible COUGAR or P89 strains. MAS and
type I RH strains were rarely rederived from the brains of
chronically infected mice; however, both strains are poor at
forming cyst walls (37), which perhaps contributes to this phe-
notype. A positive correlation between day 8 parasite burden,
weight loss, and the ability to superinfect was observed (Fig. 5C
to E). These results suggest that IRG resistance through ROP5
and ROP18 is required for Toxoplasma to promote morbidity
during a heterologous challenge and superinfection, but addi-
tional factors are necessary to endow a strain with the ability to
kill a chronically infected host.
FIG 4 The T. gondii type I ROP5/SAG3 locus is correlated with lethal secondary infection. (A) Type III (CEP) chronically infected C57BL/6 mice (day 37 of
chronic infection) were challenged with 5 104 tachyzoites of either the RH (n 2) or GT1 (n 5) type I strains; cumulative survival is plotted. (B) C57BL/6
mice were vaccinated with 106 tachyzoites of the uracil auxotroph type I RHku80ompdcup vaccine strain (83), and 34 days later mice were challenged with
either 5 104 tachyzoites of the type I RH (n 4) strain or 5 103 tachyzoites of the type I GT1 strain (n 5). Cumulative survival is plotted. (C) Type III
chronically infectedC57BL/6mice (day 34 of chronic infection)were challengedwith 5 104 tachyzoites of 16 different F1 progeny derived from a cross between
the GT1 (type I) and CTG (type III) strains. The chosen progeny have the type I CS6 marker on Toxoplasma chromosome VIIa, a marker which detects an
informative SNP in the ROP18 allele; thus, these F1 progeny express ROP18 and are 100% lethal in naive mice (34). The running LOD score for each of the 176
markers on the various Toxoplasma chromosomes and mouse survival (%) at 26 days after challenge is plotted (red line). The SAG3 marker on Toxoplasma
chromosome XII returned the highest LOD score (4.1; P 0.05). Significance was estimated based on 1,000 permutations at eachmarker; thresholds of P 0.05
and P 0.1 are shown. (D) Effects of the type I and type III SAG3 locus on mouse survival at 26 days. *, significant P value based on Student’s t test.
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The results reported here call into question the general assump-
tion that healthy T. gondii-seropositive mice are protected from
disease following reexposure and underpin several clinical obser-
vations that otherwise healthy seropositive women can develop
congenital toxoplasmosis during pregnancy upon secondary in-
fection (70). In these situations, the strain type likely matters. In
our model, we searched for Toxoplasma virulence loci that pro-
moted virulence during a secondary infection. The central mes-
sage from these studies is that evasion of the host’s IFN- response
through T. gondii virulence factors is central to host and parasite
survival during a secondary infection.
Parasite genetic determinants that influence host suscepti-
bility to reinfection. As observed in naive mouse infection stud-
ies, the Toxoplasma ROP5 and ROP18 virulence factors, which
antagonize IFN--induced IRGs, are important for parasite viru-
lence during a secondary infection. In nearly every case whenTox-
oplasma expressed the virulent alleles of ROP5 and ROP18, mor-
bidity ensued in the challenged animals, and this correlated with
the parasite burden. Importantly, strain differences in virulence
that are not observed in naive animals (because many strains have
an LD100 of 1 parasite) can be teased apart in chronically infected
mice. An unexpected outcome was the finding that the type I
strains GT1 and RH, which have a lethal dose of 1 parasite in naive
Mus musculus domesticus mice, differ in virulence in type
I-vaccinated or type III chronically infected B6mice. Genetic link-
age analysis using the F1 I  III progeny derived from the type I
GT1 and type III CTG strains implicated the type I SAG3/ROP5
locus in mediating GT1 virulence during secondary infection in
type III chronically infected B6 mice. The causative mutation un-
derlying this quantitative trait locus (QTL) peak is the subject of
ongoing investigation, but this is not the locus responsible for
FIG 5 T. gondii ROP5 and ROP18 promote superinfection. (A) C57BL/6 mice were infected with the type III strain (CEP) and allowed to progress to chronic
infection for 37 to 70 days and then challenged (i.p.) with the avirulent S22 F1 (II  III) progeny strain (n  5), engineered S22  ROP5I  ROP18II strain
(n 5), avirulent type III-Luc strain (n 4), the virulent type III ROP18I-Luc strain (n 5); the type II-Luc strain (n 4) or this strain engineered to express
the entire type I ROP5 locus via cosmid integration, II ROP5I (n 5); the virulent F1 (II III) progeny S23-Luc strain. Cumulative survival is plotted. (B)
Results obtained from the same experiment described in panel A, but the average relative weights ( SEM) of mice following secondary infection with the
indicated parasite strains are plotted. *, P 0.05; **, P 0.008 (Student’s t test was used to assess significant differences in the average relative weights between
mice challenged with engineered versus corresponding parental control strains). (C) Bioluminescence images of mice challenged with the indicated luciferase-
expressing strains on day 8 for the experiments shown in panel A. Relative parasite burden is depicted as a heat map, where the maximum andminimum values
were set to 105 and 3 103 (photons/s/cm2/sr), respectively. Asterisks indicate individual mice in which the challenging strain was detected in the brain 37 to
46 days after the secondary challenge. (D) Comparison between the average ( SEM) luciferase activity (in photons/s/cm2/sr) on day 8 after secondary challenge
of individual mice that bore evidence for superinfection (indicated with asterisks in panel C) versus mice in which superinfection was not detected. *, significant
P value, calculated with a Student’s t test. The parasite strains and mice used for this analysis are those of panel C. (E) Comparison between the average relative
weights (SEM) on day 20 of secondary challenge of mice that bore evidence for superinfection with mice in which superinfection was not detected. ***,
significant P value, calculated with a Student’s t test; significant differences between these groups were observed between days 13 and 33 of secondary infection
(data not shown). Mice that survived secondary infection and parasite strains used for this analysis are those described in panel A.
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differences in virulence between the GT1 and RH type I strains,
since genes in this region were similarly expressed and did not
encode nonsynonymous single nucleotide polymorphisms
(SNPs) between these two strains (data not shown) (81). Although
type III ROP5 gene products are highly functional and able to
synergize with ROP18 to antagonize the IRG system (84), the type
I ROP5 locus has extra copies of ROP5A and ROP5B (33, 86),
perhaps allowing for greater GTPase antagonism in immune
mice, which mount an earlier and greater IFN- response from
the T cell compartment than do naive animals. Additionally,
SAG3 is a glycosylphosphatidylinositol-linked surface protein
that binds surface glycans (87) on the host cell and is required for
virulence of the type I strain (88). SAG3 polymorphisms (5 non-
synonymous SNPs between type I and type III SAG3 alleles [data
not shown]) may cause differences in cellular tropisms between
strains, resulting in different immune evasion properties. SAG3
and ROP5 are also vaccine antigen candidates (89, 90), and a
ROP5-derived peptide epitope in B6 mice was recently described
(91). This polymorphic epitope is recognized by CD8 T cells after
infection with type II but not type I or III strains, and immuniza-
tion with dendritic cells loaded with the ROP5 epitope did not
confer protection to high-dose challenges with the type II strain.
Whether an alternative type III or type I ROP5-derived epitope is
recognized byCD8T cells and confers protection to type I second-
ary infections is unknown.
In addition to the SAG3/ROP5 locus, it is apparent that other
genetic loci are responsible for virulence in vaccinated or chroni-
cally infected animals. By analyzing recombinant F1 progeny and
various strains engineered to express virulent alleles of ROP5,
complete penetrance of the ROP5I locus in causing a lethal sec-
ondary infection was not observed. Whether the latter result re-
flects interference between cosmid-expressed and endogenous
ROP5 gene products is unknown. It should be noted that the BOF
strain encodes a single ROP5 gene (26) that is expressed at low
levels (92). Therefore, the BOF strain may be the best strain to
circumvent potential interference between cosmid-expressed and
endogenous ROP5 gene products. This may not be the case with
the II ROP5I and S22 ROP5I ROP18II strains that express
ROP5 from the endogenous ROP5II locus, which has copy num-
ber variations and divergent ROP5 isoforms compared to the
closely related type I and type III ROP5 isoforms (33). Nonethe-
less, of the three ROP5I engineered strains, the BOF  ROP5I
strain is the most resistant to IRGB6-PVM coating (26) and the
only strain that was able to kill somemice during secondary infec-
tion. The identity of additional genes that promote virulence in
chronically infectedmice andwhether they are bona fide virulence
factors or contain important immune epitopes remain to be de-
termined.
CD8 T cells and IFN- are absolute requirements for host im-
munity to the type I RH and type IIME49 strains (38), and CD8 T
cells were able to generate IFN- in response toMAS-infected cells
(Fig. 2).Whether additional CD8T cell effectormechanisms, such
as cytolysis, or other memory cell types (B and CD4 T cells) are
required for host immunity to atypicalT. gondii strains remains to
be investigated. For example, loss of CD8 T cell polyfunctionality
(i.e., the ability to produce more than one cytokine or granzyme)
correlates with host susceptibility to chronic infection (93), and
perforin-dependent cytolysis is apparently one of these required
functions (52). In contrast to chronic infection withME49 type II
strains, the perforin pathway is not required for vaccine-induced
protection against RH secondary infection (49). Whether these
differences reflect stage-specific (tachzyoite versus bradyzoite) or
TABLE 1 Superinfection of chronically infected mice challenged with IRG-resistant T. gondii strains
Challenge straina ROP18b ROP5c Chronic infection strain Fraction of mice superinfected
CEP (III) hxprt- GFP cLUC N VIR CEP (III) hxgprt 0/5
CEP (III) GFP cLUC ROP18I VIR VIR CEP (III) hxgprt 3/5d
Pru (II) GFP fLUC VIR AVIR CEP (III) hxgprt 0/4
Pru (II) GFP fLUC ROP5I VIR AVIR VIR CEP (III) hxgprt 3/5d
RH (I) GFP cLUC VIR VIR CEP (III) hxgprt 0/5
S22 (II III) N AVIR CEP (III) hxgprt 0/5
S22 (II III) ROP5I ROP18II GFP VIR AVIR VIR CEP (III) hxgprt 5/5d
S22 (II III) ROP5I ROP18II GFP VIR AVIR VIR Pru (II) hxgprt GFP fLUC 2/2e
S23 (II III) GFP cLUC VIR VIR CEP (III) hxgprt 2/5d
BOF (HG 6) VIR N CEP (III) hxgprt 0/5
BOF (HG 6) ROP5I VIR VIR CEP (III) hxgprt 1/3f
MAS (HG 4) GFP cLUC VIR VIR CEP (III) hxgprt 1/10d
GUY-KOE (HG 5) VIR VIR CEP (III) hxgprt GFP cLUC 1/1g
P89 (HG 9) N VIR CEP (III) hxgprt GFP cLUC 0/2
COUGAR (HG 11) VIR AVIR? CEP (III) hxgprt GFP cLUC 0/2
a C57BL/6 mice were chronically infected with either a type III or type II strain (genotype indicated) and challenged with atypical strains (haplogroup indicated in parentheses),
clonal strains (strain type indicated in parentheses), F1 progeny derived from a type II, type III cross (II III), or strains engineered to become IRG resistant through either
introduction of the type I ROP5 locus by cosmid integration or transgenic expression of type I or type II ROP18 genes (genotypes are indicated). At 35 to 50 days after secondary
challenge, brains from surviving mice were homogenized in PBS and used to inoculate HFF monolayers. The ensuing parasite cultures were then tested for the presence of the
challenging strain (superinfection of the brain). Data indicated are the fractions of mice in which the challenging strain was detected (with the number of mice tested as the
denominator).
b VIR, expression of ROP18, which is equated to possessing the virulent allele from either the type II or type I strain; N, the type III strain does not express ROP18.
c VIR, the ROP5 locus of the type I and III strains promotes virulence in naive mice; AVIR, the type II ROP5 alleles are less virulent; N, BOF has very low expression of ROP5;
AVIR?, it is unclear why COUGAR is IRG sensitive, but it lacks certain ROP5C isoforms.
d GFP-positive parasites were observed in the parasite culture.
e RFLP analysis of GRA6 determined that the parasite culture had the S22 GRA6III allele.
f Parasite growth was observed in mycophenolic acid-xanthine medium, which selects for parasites that carry a functional HXGPRT gene (e.g., the challenge BOF strain).
g GFP-negative parasites were observed in the parasite culture.
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strain-specific (RH versus ME49) requirements for host immu-
nity remains an open question, especially since most strains are
virulent during secondary infection, as reported here. It is clear
that some aspect of the memory CD8 T cell response but not the
CD4 T cell response is necessary for protection against RH sec-
ondary infection (42), even though both cell types make ample
amounts of IFN- after challenge (data not shown). In addition to
their cytolytic activity, which can destroy the host cell that Toxo-
plasma needs for replication, CD8 T cells express a variety of TNF
superfamilymembers which have dynamic effects onToxoplasma.
For example, parasite death can be triggered following CD40-
CD40L interactions (94, 95) and egress following FAS-FASL in-
teractions (96). Additionally, host resistance to infection is pro-
moted by lymphotoxin-alpha (48). A careful dissection of how
CD8 T cells restrict Toxoplasma may yield insights into other re-
quirements for host immunity and point to new immune path-
ways that potentially intersect Toxoplasma virulence factors, in
particular those of atypical strains.
Potential effect of superinfection onToxoplasmapopulation
structure. Although heterologous immunity to ROP5- and
ROP18-expressing Toxoplasma strains is achieved in certain
mouse genetic backgrounds, “sterile heterologous immunity”
may rarely occur. IRG-resistant strains were observed via biolu-
minescence imaging days after the initial challenge and eventually
superinfected the brain of chronically infected mice. These events
may have a significant effect on the population structure. Heter-
ologous tissue infection in intermediate hosts could assist parasite
sexual recombination in nature by allowing two strains to be pres-
ent during a single meal consumed by a felid, the definitive host
species for Toxoplasma. Mixed infections in the wild have been
noted in humans (97) and in sheep (98, 99), and heterologous
brain infections have been experimentally verified in laboratory
mice (59). Here, we linked these events to allelic combinations of
ROP5 andROP18 that resulted in resistance to IRGs, which can be
disadvantageous in naive mice because they die before the infec-
tious tissue cysts are formed, but advantageous in niches where
most intermediate hosts are chronically infected, thus facilitating
superinfection and the generation of novel parasite genotypes
upon feline infection. Although oocysts can infect cats, they are
less infectious than tissue cysts and have a much longer (3 to
10 days versus 18 to 30 days) prepatent period (or time to shed
oocysts) (100). Thus, heterologous tissue infection in intermedi-
ate hostsmay be themost efficientmeans to produce recombinant
progeny in nature.
Superinfectionmay be amajormechanism impacting the pop-
ulation structures observed on the different continents and is
likely a consequence of parasite coevolution with local rodents
and their IRGs. Unlike the clonal strains of North America and
Europe, where the vast majority of isolates are IRG sensitive, most
South American strains of the various haplogroups are not clonal
and are IRG resistant. The geographical distribution of these phe-
notypes is the subject of speculation. Certainly, theM. m. domes-
ticus house mouse that is common to North America, Western
Europe, and Africa and is highly susceptible to the type I strain has
likely shaped the dominance of the IRG-sensitive type II and III
strains in these locales. Of course, “IRG sensitive” and “IRG resis-
tance” are terms used to define the interaction between different
T. gondii strains and the IRGs of variousM. m. domesticus labora-
tory mouse strains. However, the murine IRG locus is extremely
diverse, rivaling that of the MHC, and mouse subspecies from
different geographic locations have unique IRG haplotypes that
interact with virulent Toxoplasma strains differently (101). For
example, the South-Southeast AsianM.m. castaneus subspecies of
mice does not die from type I infection, due to polymorphisms in
Irgb2-b1, and instead they form a life-long chronic infection
(101). Perhaps this is why the type I strain is frequently isolated in
Asia (5). Less is known regarding the IRG haplotypes of South
American rodents (e.g., capybara, tuco-tuco, guinea pigs), but
presumably South American Toxoplasma strains have coevolved
with these hosts to achieve maximal chronic infection. Here, we
hypothesize that once IRG resistance or optimal IRG antagonism
is selected, maintaining a clonal population structure of such
strains may be difficult when reexposure to Toxoplasma is com-
mon, for example, in South America.
Furthermore, today in North America, approximately half of
wild mammals are now chronic carriers for Toxoplasma (6), and
the domesticated cat is now highly abundant. If IRG-resistant
South America strains invade North America, as is thought to
have occurred for the generation of the type I and type III strains
(8), then changes in the clonal population structure will likely
occur as chronically infected North American hosts become su-
perinfected with South American strains. Cats feeding on those
superinfected intermediate hosts may yield strains with enhanced
virulence properties, perhaps suited to infect an immune host or a
naturally resistant host, like M. m. castaneus, but strains mal-
adapted for other hosts or species irrespective of prior exposure to
Toxoplasma.
Toxoplasma virulence factors may also impact human dis-
ease. Finally, given the lack of testing in the United States and the
proximity to South America, perhaps closer attention should be
paid to the possibility of reexposure to Toxoplasma and whether
an individual has consumed food from South American locales.
Although humans do not express the expanded small GTPase IRG
family that is antagonized by most South American strains, they
do express the large 65-kDa IFN--induced GBPs, which are in-
hibited by virulent versions of ROP5 and ROP18 (31, 102). Fur-
thermore, ROP18 induces ATF degradation, a conserved host
transcription factor that is required for T. gondii-infected den-
dritic cells to elicit CD8 T cell activation (78). Whether ROP5/18
alleles promote virulence in humans is unknown; however, type I
and atypical strain types have been associated withmultiple forms
of human toxoplasmosis (62–69). In conclusion, the selective
forces that have shaped the Toxoplasma population structure may
have the unintended consequence of generating strains that cause
severe disease in certain intermediate hosts, and we conclude that
T. gondiimay be more virulent than previously appreciated.
MATERIALS AND METHODS
Parasite strains. T. gondii strains were passaged in human foreskin fibro-
blasts (HFFs; originally obtained from the Boothroyd lab, Stanford Uni-
versity) in Toxomedium (4.5 g/liter D-glucose, L-glutamine inDulbecco’s
modified Eagle’s medium [DMEM; Life Technologies] supplemented
with 1% fetal bovine serum [FBS; Omega Scientific] and antibiotics). The
following atypical strains were used (haplogroups are shown in parenthe-
ses): CASTELLS and MAS (HG 4); GUY-KOE (HG 5); FOU, BOF, and
GPHT (HG6); CAST (HG7); TgCATBr5 (HG8); P89 (HG9); GUY-DOS
and VAND (HG 10); COUGAR (HG 11). The clonal types used in this
study were type I RH hxgprt, RH cLUC (1-1), and RH hxgprt ku80;
type II Pru hxgprt ku80, Pru A7 fLUC hxgprt::HXGPRT (5-8 B)
(103); and type III CEP hxgprt, CEP hxgprt cLUC (C22), CL14 cLUC.
The avirulent S22 (ROP5II ROP18III) and virulent S23-cLUC (ROP5II
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ROP18III) F1 progeny (85), derived from crosses between the type II and
III strains (II III), were also used. F1 progeny froma type I (GT1) type
III (CTG) cross were obtained fromBEI Resources and chosen for expres-
sion of the type I ROP18 allele inferred from restriction fragment length
polymorphism (RFLP) analysis at the CS6 genetic marker within ROP18
(http://toxomap.wustl.edu/IxIII_Typing_Table.html). F1 progeny used
to challenge chronically infected mice were E8SF, c295-31, c295-3,
B10AF, E7SF, B4SF, c285-13, c295-27, C7SF, P1A5, c295-29, c285-31,
C11AF, H7AF, c295-5, and E6AF. The BOF  ROP5I and type II (Pru
A7) ROP5I strains, which express the entire ROP5 locus from the type I
strain via integration of a cosmid (LC37), and the S22ROP5I (LC37)
ROP18IIHA strain were previously generated (26). The replication-
deficient uracil auxotroph vaccine strain RH ku80 ompdc up::HXG-
PRT (83) was maintained in medium supplemented with uracil (1 mM).
Generation of luciferase-expressing MAS strain and RH tgd057
parasite strain. A luciferase expressingMAS strain (MAS-LUC; 2C8) was
generated by transfecting a linearized dual expression plasmid harboring
the click beetle luciferase cassette (cLUC) and GFP (85), FACS sorting of
green fluorescent protein-positive (GFP) parasites, and cloning by lim-
iting dilution. The type I RH ku80 tgd057::HXGPRT strain was gener-
ated by homologous recombination via targetingwith a linearized pTKO2
“destination” plasmid (103) created by three-way Gateway cloning (Life
Technologies). The pTKO2-targeting plasmid consisted of an HXGPRT
resistance cassette flanked by 2 kb of the sequence 2,500 to 500 bp up-
stream of the ATG start site and 2 kb downstream of the stop codon of
TGD057 (TGME49_215980). RH ku80 hxgprt parasites were trans-
fected with the targeting plasmid and cloned in selection medium, which
was Toxo medium (described above) containing 50g/ml mycophenolic
acid (MPA) and 50 g/ml xanthine, as described elsewhere (103). Suc-
cessful targeting was confirmed based on absence of a PCR product with
primers specific for the endogenous TGD057 gene and by a positive PCR
product with primers internal to the HXGPRT resistance cassette and
primers that flanked the entire targeting region of the TGD057 locus, as
described in detail in Fig. S3 in the supplemental material.
Mice and generation of bone marrow-derived macrophages. Female
C57BL/6J (H-2b) mice were purchased from Jackson Laboratories and
maintained under specific-pathogen-free conditions. T57 transnuclear
mice (from the Ploegh laboratory, MIT) were bred in-house; in short,
these mice were generated by somatic cell nuclear transfer of Kb
TDG05796–103 tetramer-positive CD8 T cells (B6 background), and thus
90% of peripheral CD3 T cells are CD8 positive and 80 to 90% of these
have endogenously rearranged TCR (V6-4) and  (V13-1) loci with
encoded CDR3 regions bearing specificity for Kb-TGD05796–103 (77).
BMDMs were obtained by culturing murine bone marrow cells from
C57BL/6 mice in DMEM supplemented with 10% FBS, 1 minimal es-
sential medium nonessential amino acids, 1 mM sodium pyruvate (Life
Technologies), antibiotics, and 20% L929 conditionedmedium. BMDMs
were harvested after 7 to 8 days of differentiation (36).
Chronic infection, vaccination, and serotyping. Parasites were ob-
tained by scraping T-25 flasks containing heavily vacuolated HFFs and
sequentially syringe lysing the suspension through 25-gauge and 27-gauge
needles. The released parasites were pelleted by spinning at 572  g for
7 min, washed, and counted in phosphate-buffered saline (PBS). Mice
were infected by intraperitoneal (i.p.) injection, and parasite viability of
the inoculumwas determined in a plaque assay aftermouse infections. To
induce chronic infection, 104 tachyzoites of the type III strain (CEP) or
5 102 tachyzoites of the type II strain (Pru) were injected i.p., and mice
were allowed to progress to chronic infection (	30 days postinjection).
For vaccination with the atypical MAS strain, mice were given 400 mg/
liter (pH7.2) of sulfadiazine plus 320Mpyrimethamine (Sigma) in their
drinking water 1 day following injection of 105 MAS tachyzoites and kept
on drug therapy for 18 days. During this time, mice were boosted two
additional times with 6 105 live syringe-lysedMAS tachyzoites on day 7
and 4 104MAS parasites on day 14 after the initial injection. After drug
removal, mice were placed on normal drinking water for a minimum of
19 days prior to secondary challenge. During this time, mice exhibited no
signs of active infection and experienced weight gain, suggesting the over-
all health of the animals. For vaccination with the RH ku80 ompdc
up::HXGPRT strain, mice were injected with a single dose of 106
tachyzoites.
At least 30 days after vaccination or chronic infection, blood was har-
vested from mice via the tail vein, collected in tubes containing 5 l of
0.5 M EDTA, and placed on ice. The blood was pelleted at 5,800  g for
5 min; blood plasma was collected from the supernatant and stored at
80°C. To determine seroconversion, HFFs were grown on coverslips
and infected with the GFP-expressing type I RH (1-1) strain overnight,
fixed the nextmorningwith 3% formaldehyde in PBS, permeabilizedwith
3% bovine serum albumin, 0.2 Triton X-100–0.01% sodium azide, incu-
bated with a 1:100 dilution of collected blood plasma for 2 h at room
temperature or overnight at 4°C, washed, and detected with Alexa Fluor
594-labeled secondary antibodies specific for mouse IgG (Invitrogen).
“Plasma-stained” parasites were observed by immunofluorescence.
Secondary infections, assessment of parasite viability, and biolumi-
nescence imaging. Seropositive mice were then challenged with syringe-
lysed tachyzoites (5  104) and weighed every 3 to 4 days. After the last
mouse injection, parasite viability for each strain was determined by a
plaque assay in which 100 tachyzoites were plated in HFF monolayers
grown in a 24-well plate; 5 to 7 days later plaques were enumerated by
microscopy (4 objective). Viability ranged from 20 to 50%. For in vivo
bioluminescence imaging, mice were injected i.p. with 300 g of
D-luciferin (Gold Biotechnology) and 5 min later anesthetized with iso-
flurane (Abbott); 5 min later, photon emission from individual mice was
detected with an IVIS Spectrum bioluminescent and fluorescent imaging
system (Xenogen). Images were captured with integration times from 10 s
to 5 min, depending on the intensity of the bioluminescent signal. Image
analysis was performed with Living Image software (Xenogen).
Genetic linkage analysis. For QTL analysis, 176 informative genetic
markers for each of the F1 I III progeny were obtained from the website
http://toxomap.wustl.edu/IxIII_Typing_Table.html, and mouse survival
(as a percentage of total mice) at 26 days after secondary infection in type
III chronically infected C57BL/6 mice was analyzed with the program
R/QTL (Bowman). LOD scores for each marker were calculated. For all
LOD scores of	2, 1,000 permutationswere performed to obtain the LOD
threshold at a P level of0.05, which was considered statistically signifi-
cant; only the SAG3marker returned an LOD score of	2 and was signif-
icant for this experiment.
Brain superinfection assays. Brains were dissected from chronically
infected mice that survived secondary challenge, rinsed in PBS, placed in
5 ml PBS, and extruded through a 2-inch 21-gauge needle several times
(10-ml syringe). The suspension was spun at 572  g for 7 min and
resuspended in 1 ml of PBS. For rederivation, 100 to 200 l of the brain
homogenate was used to inoculate HFF monolayers in a T-25 flask with
Toxo medium (described above). One week after inoculation, the T-25
flask was scraped and syringe lysed through a 25-gauge needle, spun for
5 min at 32  g to pellet the large debris; the supernatant was collected,
pelleted with a faster spin of 572 g for 7 min, and resuspended in Toxo
medium, and the entirety was used to inoculate a new HFF monolayer in
a T-25 flask. Parasite growthwas typically observed between 2 and 3weeks
post-initial inoculation. To determine whether the challenging strain was
present in the ensuing parasite culture, several approaches were used:
parasite expression of GFP or lack thereof was directly observed in the
culture by florescence microscopy; parasites were passed in selection me-
dium containingMPA-xanthine (described above) to test for a functional
copy of HXGPRT; parasite genomic DNA was isolated using DNAzol
(Invitrogen); RFLP analysis of the GRA6 locus was performed using the
primers GRA6FW (5=-ATTTGTGTTTCCGAGCAGGT) and GRA6RV
(3=-TCGCCGAAGAGTTGACATAG), and the restriction enzymeMseI,
producing unique fragment lengths that identified all three clonal
lineages.
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Cell isolation, in vitro recall infections, and FACS analysis. PECs
were harvested by injecting 4ml of PBS plus 3ml of air into the peritoneal
cavity (i.p.) with a 30-gauge needle and shaking and extracting the cells by
puncture with a 16-gauge needle. Cells were filtered through 70-m cell
strainer and washed in FACS buffer, 1% FBS–PBS before staining. The
spleen or, in the case of T57 mice, the spleen and lymph nodes were
dissected and crushed through a cell strainer, pelleted, and incubated in
ACK red blood cell (RBC) lysis buffer (NH4Cl at 0.15 M, KHCO3 at
10 mM, EDTA at 0.1 mM) for 5 min at room temperature, washed in
FACS buffer, and filtered again through a cell strainer.
For FACS analysis, all preparations were done on ice, and cells were
blocked in FACS buffer supplemented with 10% normal hamster serum
(Jackson ImmunoResearch) and FcBlock anti-CD16/32 (BD Pharmin-
gen) prior to staining with fluorophore-labeled monoclonal antibodies
(MAbs). The following MAbs (1:100 staining dilutions) were purchased
from eBioscience unless otherwise stated: anti-CD62L eFluor 450
(MEL-14), anti-CD44 eFluor 450 (IM7), anti-KLRG1–fluorescein iso-
thiocyanate (FITC) (2F1), anti-CD127–phycoerythrin (PE) (A7R34),
anti-CD19–PE-Cy5 (1D3), anti-CD8–allophycocyanin (APC) or anti-
CD8–PE-Cy7 (53-6.7), and anti-CD3 APC-Cy7 (145-2C11; BD
Pharmingen). Cells were washed in FACS buffer prior to analysis on an
LSRHTS-2 FACSmachine (BD) equipped with BD FACSDIVA software.
For intracellular staining of cells following in vitro recall infections,
6  105 PECs or splenocytes per well (96-well plate) were plated in
T cell medium (10% FBS in RPMI 1640 with GlutaMAX, antibiotics,
10 mM HEPES, 1 mM sodium pyruvate [Invitrogen], and 1.75 l
-mercaptoethanol per 500 ml [MP Biomedicals]). Cells were infected
with parasites (multiplicity of infection [MOI], 0.2) for 18 to 21 h, and
3 g/ml brefeldin A (eBioscience) was added for the last 5 h of infection.
Tissue culture plates were placed on ice, and cells were harvested by pi-
petting, washed with FACS buffer, blocked, and stained for surface mark-
ers as described above. Cells were then fixed with BD Cytofix/Cytoperm
and permeabilized with BD Perm/Wash solution according to the manu-
facturer’s suggestions (BD Pharmingen). Cells were stained with MAbs
labeled with APC or PE that recognized IFN- (XMG1.2) at room tem-
perature for 1 h or overnight at 4°C. Cells were then washed once in BD
Perm/Wash and once in FACS buffer prior to FACS analysis. All data were
compensated and processed with FlowJo software (Treestar).
T57 transnuclear CD8 T cell cytokine secretion. BMDMs (B6) cells
were plated at 2  105 cell/well (96-well plate) in BMDM medium (de-
scribed above) supplemented with 20% L929 conditioned medium. The
next day, the medium was removed and cells were infected with parasites
in triplicate (MOI, 0.6, 0.2, or 0.08) in T cell medium (see above). Spleno-
cytes and lymph node cells from T57 transnuclear mice were harvested
and combined, and RBCswere lysed with ACK lysis buffer. After washing,
5  105 cells were added to the infected BMDMs (~2 h from time of
infection). Forty-eight hours later, supernatantwas removed and stored at
80°C for IL-2 and IFN- analysis by ELISA (eBioscience). Viability was
inferred via a plaque assay, and wells with equivalent numbers of viable
parasites were compared.
Ethics statement. All mouse work was performed in accordance with
the recommendations in the Guide to the Care and Use of Laboratory
Animals (104) of the National Institutes of Health. The MIT Committee
onAnimal Care (assurance no. A-3125-01) approved all protocols, and all
efforts were made to minimize unnecessary distress to the animals.
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